These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 16991089

  • 1. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.
    Cilmi SA, Karalius BJ, Choy W, Smith RN, Butterton JR.
    J Infect Dis; 2006 Oct 15; 194(8):1135-40. PubMed ID: 16991089
    [Abstract] [Full Text] [Related]

  • 2. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M, Matsuoka K, Kita E, Igai K, Higashi N, Miyagawa A, Watanabe T, Yanoshita R, Samejima Y, Terunuma D, Natori Y, Nishikawa K.
    J Infect Dis; 2004 Feb 01; 189(3):360-8. PubMed ID: 14745692
    [Abstract] [Full Text] [Related]

  • 3. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins.
    Liu J, Sun Y, Feng S, Zhu L, Guo X, Qi C.
    Vaccine; 2009 Oct 09; 27(43):5929-35. PubMed ID: 19682616
    [Abstract] [Full Text] [Related]

  • 4. Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity.
    Shimizu T, Sato T, Kawakami S, Ohta T, Noda M, Hamabata T.
    Microb Pathog; 2007 Oct 09; 43(2-3):88-95. PubMed ID: 17532600
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An in vitro model of Fabry disease.
    Shu L, Murphy HS, Cooling L, Shayman JA.
    J Am Soc Nephrol; 2005 Sep 09; 16(9):2636-45. PubMed ID: 16033856
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7.
    Kita E, Yunou Y, Kurioka T, Harada H, Yoshikawa S, Mikasa K, Higashi N.
    Infect Immun; 2000 Mar 09; 68(3):1207-14. PubMed ID: 10678928
    [Abstract] [Full Text] [Related]

  • 9. Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.
    Hoffman MA, Menge C, Casey TA, Laegreid W, Bosworth BT, Dean-Nystrom EA.
    Clin Vaccine Immunol; 2006 Dec 09; 13(12):1322-7. PubMed ID: 17050743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli.
    Shimizu T, Kawakami S, Sato T, Sasaki T, Higashide M, Hamabata T, Ohta T, Noda M.
    Infect Immun; 2007 May 09; 75(5):2189-200. PubMed ID: 17325057
    [Abstract] [Full Text] [Related]

  • 12. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.
    Mulvey GL, Marcato P, Kitov PI, Sadowska J, Bundle DR, Armstrong GD.
    J Infect Dis; 2003 Feb 15; 187(4):640-9. PubMed ID: 12599081
    [Abstract] [Full Text] [Related]

  • 13. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW, Zhang W, Bielaszewska M, Mellmann A, Köck R, Fruth A, Tschäpe H, Karch H.
    Clin Infect Dis; 2007 Jul 01; 45(1):39-45. PubMed ID: 17554698
    [Abstract] [Full Text] [Related]

  • 14. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC.
    Neurobiol Dis; 2009 Jan 01; 33(1):48-56. PubMed ID: 18848893
    [Abstract] [Full Text] [Related]

  • 15. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit.
    Zeidner KM, Desnick RJ, Ioannou YA.
    Anal Biochem; 1999 Feb 01; 267(1):104-13. PubMed ID: 9918661
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
    Karmali MA.
    J Infect Dis; 2004 Feb 01; 189(3):355-9. PubMed ID: 14745691
    [No Abstract] [Full Text] [Related]

  • 18. Shiga toxin mode of action in E. coli O157:H7 disease.
    Obrig TG.
    Front Biosci; 1997 Dec 15; 2():d635-42. PubMed ID: 9392626
    [Abstract] [Full Text] [Related]

  • 19. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA, De Francesco NP, Borrajo GJ, Ceci R, Fossati CA.
    Clin Chim Acta; 2009 May 15; 403(1-2):194-7. PubMed ID: 19268437
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006.
    Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, Smith KE.
    Clin Infect Dis; 2009 Aug 01; 49(3):358-64. PubMed ID: 19548834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.